Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
3.620
+0.240 (7.10%)
At close: Aug 12, 2025, 4:00 PM
3.590
-0.030 (-0.83%)
After-hours: Aug 12, 2025, 7:25 PM EDT
United States Steel Employees
Altimmune had 59 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
59
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$339
Profits / Employee
-$1,487,220
Market Cap
293.61M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 59 | 0 | - |
Dec 31, 2023 | 59 | 7 | 13.46% |
Dec 31, 2022 | 52 | 5 | 10.64% |
Dec 31, 2021 | 47 | 4 | 9.30% |
Dec 31, 2020 | 43 | 18 | 72.00% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ALT News
- 17 hours ago - Altimmune Announces Second Quarter 2025 Financial Results and Business Update - GlobeNewsWire
- 1 day ago - Altimmune Board of Directors Appoints Jerry Durso as Chairman - GlobeNewsWire
- 7 days ago - Altimmune to Report Second Quarter 2025 Financial Results and Provide Business Update on August 12, 2025 - GlobeNewsWire
- 24 days ago - ALT Investors Have Opportunity to Join Altimmune, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 4 weeks ago - Altimmune Announces Initiation of RESTORE Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol-Associated Liver Disease (ALD) - GlobeNewsWire
- 6 weeks ago - Altimmune's Fatty Liver Candidate Faces Differentiation Doubts - Benzinga
- 6 weeks ago - Altimmune: Deciphering The MASH Crash (Rating Upgrade) - Seeking Alpha
- 6 weeks ago - Altimmune: FDA Path Forward Remains Despite Mixed MASH Treatment Data Of Pemvidutide - Seeking Alpha